{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:44:17Z","timestamp":1793195057137,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that occurs on a background of bone marrow failure (BMF). In PNH, chronic intravascular hemolysis causes an increase in morbidity and mortality, mainly because of thromboses. Over the last 20 years, treatment of PNH has focused on the complement protein C5 to prevent intravascular hemolysis using the monoclonal antibody eculizumab and more recently ravulizumab. In the United Kingdom, all patients are under review at 1 of 2 reference centers. We report on all 509 UK patients with PNH treated with eculizumab and\/or ravulizumab between May 2002 and July 2022. The survival of patients with eculizumab and ravulizumab was significantly lower than that of age- and sex-matched controls (P\u00a0= .001). Only 4 patients died of thromboses. The survival of patients with PNH (n\u00a0= 389), when those requiring treatment for BMF (clonal evolution to myelodysplastic syndrome or acute leukemia or had progressive unresponsive aplastic anemia) were excluded, was not significantly different from that of age- and sex-matched controls (P\u00a0= .12). There were 11 cases of meningococcal sepsis (0.35 events per 100 patient-years). Extravascular hemolysis was evident in patients who received treatment, with 26.7% of patients requiring transfusions in the most recent 12 months on therapy. Eculizumab and ravulizumab are safe and effective therapies that reduce mortality and morbidity in PNH, but further work is needed to reduce mortality in those with concomitant BMF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023021762","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:07:19Z","timestamp":1703405239000},"page":"1157-1166","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":53,"title":["Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria"],"prefix":"10.1182","volume":"143","author":[{"given":"Richard J.","family":"Kelly","sequence":"first","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0685-1543","authenticated-orcid":false,"given":"Matthew","family":"Holt","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-3014","authenticated-orcid":false,"given":"Jennifer","family":"Vidler","sequence":"additional","affiliation":[{"name":"2Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Large","sequence":"additional","affiliation":[{"name":"2Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briony","family":"Forrest","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Barnfield","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-421X","authenticated-orcid":false,"given":"Alexandra","family":"Pike","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"Griffin","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-3882","authenticated-orcid":false,"given":"Petra","family":"Muus","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-5317","authenticated-orcid":false,"given":"Sateesh K.","family":"Nagumantry","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Peterborough City Hospital, Peterborough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Varghese","sequence":"additional","affiliation":[{"name":"1Department of Haematology, St. James\u2019s University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Davies","sequence":"additional","affiliation":[{"name":"4School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roochi","family":"Trikha","sequence":"additional","affiliation":[{"name":"2Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin G.","family":"Kulasekararaj","sequence":"additional","affiliation":[{"name":"2Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Mitchell","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Monklands Hospital, Airdrie, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyans","family":"Gandhi","sequence":"additional","affiliation":[{"name":"2Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5099","key":"2024032115211706000_bib1","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.7680492","article-title":"The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis","volume":"259","author":"Miyata","year":"1993","journal-title":"Science"},{"issue":"4","key":"2024032115211706000_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"issue":"4","key":"2024032115211706000_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJM199401273300404","article-title":"Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria","volume":"330","author":"Miyata","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024032115211706000_bib4","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2024032115211706000_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood.V30.2.251.251","article-title":"Riddle: what do aplastic anemia. Paroxysmal nocturnal hemoglobinuria (PNH) and \u2018hypoplastic\u2019 leukemia have in common?","volume":"30","author":"Dameshek","year":"1967","journal-title":"Blood"},{"issue":"suppl 2","key":"2024032115211706000_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/BF03165111","article-title":"The relationship of aplastic anemia and PNH","volume":"76","author":"Young","year":"2002","journal-title":"Int J Hematol"},{"issue":"5","key":"2024032115211706000_bib7","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1182\/blood.V85.5.1354.bloodjournal8551354","article-title":"Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link","volume":"85","author":"Griscelli-Bennaceur","year":"1995","journal-title":"Blood"},{"issue":"1","key":"2024032115211706000_bib8","first-page":"81","article-title":"A\u00a0pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anaemia patients with a deficiency of phosphatidylinositol glycan anchored proteins","volume":"23","author":"Schrezenmeier","year":"1995","journal-title":"Exp Hematol"},{"issue":"6","key":"2024032115211706000_bib9","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood.V79.6.1400.1400","article-title":"Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes","volume":"79","author":"Mahoney","year":"1992","journal-title":"Blood"},{"issue":"27","key":"2024032115211706000_bib10","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1021\/bi8006324","article-title":"The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins","volume":"47","author":"Paulick","year":"2008","journal-title":"Biochemistry"},{"issue":"2","key":"2024032115211706000_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.jbchem.a021746","article-title":"GPI-anchor synthesis in mammalian cells: genes, their products, and a deficiency","volume":"122","author":"Kinoshita","year":"1997","journal-title":"J\u00a0Biochem"},{"issue":"19","key":"2024032115211706000_bib12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024032115211706000_bib13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2013.093161","article-title":"Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"99","author":"Schrezenmeier","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2024032115211706000_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1160\/TH04-06-0391","article-title":"High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria","volume":"93","author":"Araten","year":"2005","journal-title":"Thromb Haemost"},{"issue":"8","key":"2024032115211706000_bib15","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"French Society of Hematology, French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"de Latour","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2024032115211706000_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","article-title":"Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays","volume":"126","author":"Moyo","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"2024032115211706000_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.md.0000126763.68170.46","article-title":"Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan","volume":"83","author":"Nishimura","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"9027","key":"2024032115211706000_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors","volume":"348","author":"Soci\u00e9","year":"1996","journal-title":"Lancet"},{"issue":"25","key":"2024032115211706000_bib19","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"17-18","key":"2024032115211706000_bib20","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain\u00a0Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"issue":"11","key":"2024032115211706000_bib21","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2024032115211706000_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024032115211706000_bib23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024032115211706000_bib24","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2024032115211706000_bib25","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2024032115211706000_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","article-title":"Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria","volume":"85","author":"Hillmen","year":"2010","journal-title":"Am J Hematol"},{"issue":"3","key":"2024032115211706000_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","article-title":"Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria","volume":"149","author":"Hill","year":"2010","journal-title":"Br J Haematol"},{"issue":"25","key":"2024032115211706000_bib28","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024032115211706000_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2024032115211706000_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"17","key":"2024032115211706000_bib31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic anemia","volume":"379","author":"Young","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2024032115211706000_bib32","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2017-09-807859","article-title":"Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?","volume":"131","author":"Giammarco","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2024032115211706000_bib33","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A\u00a0randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2024032115211706000_bib34","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2024032115211706000_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/12\/1157\/2218449\/blood_bld-2023-021762-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/12\/1157\/2218449\/blood_bld-2023-021762-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:21:56Z","timestamp":1711020116000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/12\/1157\/506720\/Treatment-outcomes-of-complement-protein-C5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,3,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021762","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]}}}